1117-66-4

Basic information

• Product Name: 7-AMINO-HEPTANOIC ACID HCL ,98.0+%
• Synonyms: 7-AMINO-HEPTANOIC ACID HCL ,98.0+%;Heptanoic acid, 7-aMino-, ethyl esterr;Heptanoic acid, 7-aMino-, ethyl ester
• CAS NO: 1117-66-4
• Molecular Formula: C₉H₁₉NO₂
• Molecular Weight: 173.25
• Mol File: 1117-66-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 231.511 °C at 760 mmHg
• Flash Point: 98.272 °C
• Appearance: /
• Density: 0.94 g/cm³
• Vapor Pressure: 0.062mmHg at 25°C
• Refractive Index: 1.445
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.61±0.10(Predicted)
• CAS DataBase Reference: 7-AMINO-HEPTANOIC ACID HCL ,98.0+%(CAS DataBase Reference)
• NIST Chemistry Reference: 7-AMINO-HEPTANOIC ACID HCL ,98.0+%(1117-66-4)
• EPA Substance Registry System: 7-AMINO-HEPTANOIC ACID HCL ,98.0+%(1117-66-4)

Safety Data

• Hazardous Substances Data: 1117-66-4(Hazardous Substances Data)

Usage

General Description

7-Amino-heptanoic acid HCl, 98.0+% is a chemical compound that is commonly used in chemical research and development. It is a white to off-white crystalline powder with a purity of at least 98.0%. This chemical is an amino acid derivative, with a seven-carbon chain and an amino group. It is often used as a building block for organic synthesis and can be used in the production of various pharmaceuticals and other bioactive compounds. 7-AMINO-HEPTANOIC ACID HCL ,98.0+% is stable under normal storage conditions and is typically handled and stored in a dry, cool, and well-ventilated area. It is important to use proper safety precautions when handling and working with this chemical, as it can be irritant to the eyes, skin, and respiratory system.

InChI:InChI=1/C9H19NO2/c1-2-12-9(11)7-5-3-4-6-8-10/h2-8,10H2,1H3

Upstream product

• 76455-55-5 ethyl ζ-nitroheptanoate 
• 502-44-3 hexahydro-2H-oxepin-2-one 
• 64-17-5 ethanol 
• 143-33-9 sodium cyanide 
• 10137-65-2 ethyl 6-cyanohexanoate 
• 929-17-9 7-aminoheptanoic acid 
• 29823-18-5 ethyl 7-bromoheptanoate 
• 1313585-64-6 C₃₇H₄₀F₁₇NO₅ 
• 1313585-79-3 ethyl 7-(((4-(2-perfluoroctylethyl)benzyl)oxy)amino)heptanoate hydrochloride 
• 1313585-47-5 ethyl 7-(tert-butoxycarbonyl(4-(2-perfluoroctylethyl)benzyloxy)amino)heptanoate 
• 927831-56-9 ethyl 7-azidoheptanoate 
• 25542-62-5 6-bromo-hexanoic acid ethyl ester 
• 4224-70-8 6-bromohexanoic acid 

Downstream Products

• 191172-75-5 tianeptine 
• 66981-77-9 ethyl 7-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)heptanoate 
• 1254178-08-9 C₅₂H₅₇N₇O₄ 

Relevant articles and documents

Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma

Multiple myeloma (MM) is the second most common haematological malignancy. Almost all patients with MM eventually relapse, and most recommended treatment protocols for the patients with relapsed refractory MM comprise a combination of drugs with different mechanisms of action. Therefore novel drugs are in urgent need in clinic. Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions. In this study, a series of Bcl-2/HDAC dual-target inhibitors were designed and synthesized. Among them, compounds 7e–7g showed good inhibitory activities against HDAC6 and high binding affinities to Bcl-2 protein simultaneously. They also displayed good growth inhibitory activities against human MM cell line RPMI-8226, which proved their potential value for the treatment of multiple myeloma.

Synthesis of N-alkylated amino acids using fluorous-tagged hydroxylamines

The development of a new fluorous-tagged ammonia-equivalent for the synthesis of N-alkylated amino acids is described. The required building blocks were readily accessed in high yield and purity using F-SPE purification technique. Coupling of the fluorous

SULFONAMIDES

The present invention provides R, R1, R2, R3, X, c, d, e, f, g, x, y, a, b, z and n are defined in the specification. These compounds are useful in lowering IOP and/or treating glaucoma or providing neuroprotection to the